This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
design method | 318 |
united states | 267 |
respiratory syndrome | 253 |
infectious diseases | 242 |
influenza virus | 214 |
virus infection | 210 |
middle east | 190 |
bone marrow | 187 |
infectious disease | 176 |
acute respiratory | 173 |
respiratory syncytial | 171 |
east respiratory | 171 |
public health | 170 |
syncytial virus | 166 |
respiratory tract | 166 |
states background | 148 |
immune response | 139 |
pediatric patients | 135 |
syndrome coronavirus | 132 |
risk factors | 123 |
stem cell | 102 |
sickle cell | 102 |
respiratory viruses | 98 |
severe acute | 95 |
cov infection | 94 |
viral infection | 92 |
cord uid | 91 |
doc id | 91 |
infected cells | 90 |
avian influenza | 89 |
porcine epidemic | 88 |
cell lines | 88 |
escherichia coli | 85 |
lower respiratory | 84 |
immune responses | 81 |
cell disease | 79 |
epidemic diarrhea | 79 |
mg kg | 79 |
zika virus | 77 |
like particles | 77 |
viral infections | 75 |
significantly higher | 72 |
statistically significant | 72 |
median age | 69 |
health care | 68 |
influenza infection | 68 |
cerebral malaria | 67 |
chart review | 67 |
clinical trials | 66 |
diarrhea virus | 65 |
highly infectious | 65 |
innate immune | 64 |
prone positioning | 64 |
blood cultures | 64 |
vlp vaccines | 63 |
epithelial cells | 63 |
respiratory distress | 63 |
staphylococcus aureus | 63 |
monoclonal antibody | 61 |
gene expression | 61 |
one patient | 61 |
viral rna | 61 |
blood culture | 60 |
pediatric oncology | 60 |
age group | 60 |
cov ma | 58 |
increased risk | 58 |
retrospective chart | 58 |
disease control | 57 |
blood cell | 57 |
red blood | 56 |
cell surface | 56 |
hematopoietic stem | 56 |
years old | 55 |
high risk | 55 |
previously described | 55 |
previous studies | 55 |
time pcr | 54 |
chain reaction | 54 |
adjuvanted wiv | 54 |
viral replication | 54 |
polymerase chain | 54 |
patients received | 54 |
control group | 54 |
acquired pneumonia | 53 |
cell line | 53 |
lymphoblastic leukemia | 53 |
age groups | 52 |
type i | 52 |
parainfluenza virus | 52 |
deep learning | 52 |
highly pathogenic | 51 |
performed using | 51 |
acute lymphoblastic | 51 |
mean age | 51 |
viral load | 50 |
cell transplant | 49 |
vero cells | 49 |
present study | 48 |
cell transplantation | 48 |
distress syndrome | 48 |
papn ectodomain | 48 |
flow cytometry | 48 |
rna viruses | 47 |
cell culture | 47 |
influenza viruses | 47 |
south korea | 47 |
young children | 47 |
medicinal plants | 47 |
prediction model | 47 |
ebola virus | 46 |
pandemic influenza | 46 |
childhood cancer | 46 |
virus replication | 46 |
respiratory infections | 46 |
infection control | 46 |
important role | 45 |
may also | 45 |
influenza vaccine | 45 |
human papillomavirus | 45 |
infectious remains | 45 |
medical center | 44 |
platelet count | 44 |
clinical outcomes | 44 |
en el | 44 |
arbaeen ceremony | 44 |
significant differences | 44 |
respiratory virus | 44 |
transplant recipients | 44 |
virus infections | 44 |
health system | 43 |
peripheral blood | 43 |
mass spectrometry | 43 |
hong kong | 43 |
intensive care | 43 |
infectious bronchitis | 43 |
days post | 42 |
tract infection | 42 |
old male | 42 |
tract infections | 42 |
systematic review | 41 |
described previously | 41 |
fresh produce | 41 |
respiratory viral | 41 |
human metapneumovirus | 41 |
irrigation water | 41 |
influenza pandemic | 41 |
spinal cord | 40 |
oncology patients | 40 |
hospitalized patients | 40 |
least one | 40 |
nucleic acid | 40 |
world health | 40 |
antiviral activity | 40 |
mf prevalence | 39 |
patients aged | 39 |
amino acid | 39 |
two patients | 39 |
hh performance | 38 |
old female | 38 |
young adults | 38 |
emerging infectious | 38 |
saudi arabia | 38 |
disease severity | 38 |
health organization | 38 |
weight loss | 38 |
vaccine development | 37 |
side effects | 37 |
overall survival | 37 |
dendritic cells | 37 |
combination therapy | 37 |
monoclonal antibodies | 37 |
stranded rna | 36 |
kul cells | 36 |
disease virus | 36 |
enveloped viruses | 36 |
protein expression | 36 |
respiratory failure | 36 |
retrospective study | 36 |
vaccination strategies | 36 |
immune system | 36 |
human parainfluenza | 36 |
adult patients | 36 |
antiviral activities | 36 |
plasmodium falciparum | 36 |
blood cells | 36 |
optimal control | 36 |
like particle | 35 |
clinical samples | 35 |
wild birds | 35 |
statistical significance | 35 |
time points | 35 |
pediatric hematology | 35 |
morpholino oligomers | 35 |
infected mice | 35 |
data subset | 35 |
three patients | 34 |
pediatric cancer | 34 |
wiv formulations | 34 |
room temperature | 34 |
case series | 33 |
virus type | 33 |
mouse model | 33 |
inflammatory cytokines | 33 |
newly diagnosed | 33 |
emergency department | 33 |
coronavirus infection | 33 |
patients receiving | 33 |
patients treated | 33 |
tumor cells | 32 |
lung injury | 32 |
surveillance data | 32 |
attenuated rabv | 32 |
driving pressure | 32 |
bronchitis virus | 32 |
class i | 32 |
cohort study | 32 |
antiviral agents | 32 |
upper respiratory | 32 |
western blot | 32 |
determine whether | 32 |
spike protein | 32 |
myeloid leukemia | 31 |
cystic fibrosis | 31 |
year old | 31 |
zikv infection | 31 |
clinical trial | 31 |
body weight | 31 |
respiratory symptoms | 31 |
blood samples | 31 |
solid tumors | 30 |
mdbk cells | 30 |
bovine respiratory | 30 |
live poultry | 30 |
recent years | 30 |
electron microscopy | 30 |
data suggest | 30 |
expression levels | 30 |
pseudomonas aeruginosa | 30 |
signaling pathway | 30 |
clinical characteristics | 30 |
lung transplant | 30 |
cancer survivors | 30 |
respiratory disease | 30 |
children aged | 30 |
clinical practice | 30 |
lymph nodes | 29 |
retrospective review | 29 |
disease transmission | 29 |
significant difference | 29 |
significantly lower | 29 |
staining intensity | 29 |
well plates | 29 |
pathogenic avian | 29 |
microbial forensics | 29 |
time series | 29 |
local containment | 29 |
prospective study | 29 |
olfactory bulb | 29 |
siq model | 29 |
nervous system | 29 |
taken together | 29 |
acute myeloid | 28 |
authors declare | 28 |
cov nsp | 28 |
surveillance system | 28 |
pandemic period | 28 |
new york | 28 |
bacterial infections | 28 |
spectrum antiviral | 28 |
informed consent | 28 |
neutralizing antibodies | 28 |
significantly different | 28 |
day mortality | 28 |
cell proliferation | 27 |
animal models | 27 |
binding site | 27 |
mers outbreak | 27 |
data streams | 27 |
iron overload | 27 |
virus titers | 27 |
health surveillance | 27 |
lung disease | 27 |
analyzed using | 27 |
cell death | 27 |
decision making | 27 |
mortality rate | 27 |
like receptor | 27 |
pediatric population | 27 |
en las | 27 |
infected patients | 27 |
receptor binding | 27 |
even though | 26 |
endou activity | 26 |
central nervous | 26 |
hematopoietic cell | 26 |
critically ill | 26 |
somatic mutations | 26 |
rabies virus | 26 |
study period | 26 |
gold nanoparticles | 26 |
i ifn | 26 |
vlp vaccine | 26 |
statistical analysis | 26 |
mortality rates | 26 |
hodgkin lymphoma | 26 |
dependent manner | 26 |
en los | 26 |
cell cultures | 26 |
dnn model | 26 |
reverse transcription | 26 |
herpes simplex | 26 |
wt rabv | 25 |
interaction patterns | 25 |
conventional method | 25 |
acute chest | 25 |
severe disease | 25 |
viral respiratory | 25 |
macromolecular prodrugs | 25 |
clinical signs | 25 |
ppmo targeting | 25 |
seasonal influenza | 25 |
hematology oncology | 25 |
current study | 25 |
four patients | 25 |
replacement therapy | 25 |
dimer interface | 25 |
diagnostic tests | 25 |
mhc class | 25 |
clinical features | 25 |
innate immunity | 25 |
panc cells | 25 |
arima model | 25 |
kg day | 25 |
hand hygiene | 25 |
risk factor | 25 |
lstm models | 25 |
results showed | 25 |
clinical severity | 25 |
medical records | 25 |
factor viii | 25 |
prediction rule | 24 |
survival rates | 24 |
chest syndrome | 24 |
confidence interval | 24 |
also known | 24 |
two groups | 24 |
risk assessment | 24 |
simplex virus | 24 |
also found | 24 |
among children | 24 |
blood vessels | 24 |
standard deviation | 24 |
fungal infections | 24 |
reaction mixture | 24 |
retrospective cohort | 24 |
data collected | 24 |
ards patients | 24 |
long term | 24 |
findings suggest | 24 |
confirmed cases | 24 |
marrow failure | 24 |
clinical course | 24 |
inclusion criteria | 24 |
reverse transcriptase | 24 |
disease surveillance | 23 |
el tratamiento | 23 |
social interaction | 23 |
regression analysis | 23 |
five patients | 23 |
mg ml | 23 |
mechanical ventilation | 23 |
significantly decreased | 23 |
immune cells | 23 |
large number | 23 |
nk cells | 23 |
wilms tumor | 23 |
viral diseases | 23 |
ma infection | 23 |
histone acetylation | 23 |
virus disease | 23 |
bacterial infection | 23 |
significantly reduced | 23 |
hela cells | 23 |
lstm model | 23 |
complement system | 23 |
rhinovirus infection | 23 |
marrow transplantation | 23 |
cells infected | 23 |
clodronate liposomes | 23 |
care unit | 23 |
severe ards | 23 |
bovine herpesvirus | 23 |
aerosol method | 23 |
patient population | 23 |
endothelial cells | 23 |
linear regression | 22 |
three times | 22 |
median time | 22 |
immunodeficiency virus | 22 |
hemolytic anemia | 22 |
social media | 22 |
clinical data | 22 |
incubation period | 22 |
white blood | 22 |
positive patients | 22 |
plasmodium parasites | 22 |
patients diagnosed | 22 |
invasive aspergillosis | 22 |
host cells | 22 |
lactam monotherapy | 22 |
control measures | 22 |
activation function | 22 |
previous study | 22 |
results suggest | 22 |
rsv infection | 22 |
neutralizing mabs | 22 |
influenza pneumonia | 22 |
patients undergoing | 22 |
data assimilation | 22 |
enteric pathogens | 22 |
tgev antigen | 22 |
young adult | 22 |
results show | 22 |
recombinant ibv | 22 |
negative control | 22 |
mediated antiviral | 21 |
hbv infection | 21 |
neutralizing activity | 21 |
cell membrane | 21 |
population immunity | 21 |
radiation therapy | 21 |
crystal structure | 21 |
respiratory illness | 21 |
disease outbreaks | 21 |
exome sequencing | 21 |
renal replacement | 21 |
ct scan | 21 |
naturally occurring | 21 |
viral titers | 21 |
high prevalence | 21 |
barr virus | 21 |
analysis showed | 21 |
platelet counts | 21 |
dynamic driving | 21 |
class ii | 21 |
cell responses | 21 |
generation sequencing | 21 |
clinical presentation | 21 |
pcr assay | 21 |
method group | 21 |
lymphatic filariasis | 21 |
human pathogens | 21 |
small molecule | 21 |
tumor growth | 21 |
significantly increased | 20 |
supportive care | 20 |
positive blood | 20 |
membrane fusion | 20 |
previously reported | 20 |
data collection | 20 |
transmissible gastroenteritis | 20 |
best performance | 20 |
hi titers | 20 |
streptococcus pneumoniae | 20 |
membranotropic peptides | 20 |
model predictions | 20 |
human coronavirus | 20 |
time reverse | 20 |
study area | 20 |
metastatic disease | 20 |
following infection | 20 |
older age | 20 |
papillomavirus type | 20 |
i interferon | 20 |
future studies | 20 |
pregnant mice | 20 |
critical role | 20 |
study demonstrated | 20 |
human immunodeficiency | 20 |
antigen presentation | 20 |
first step | 20 |
logistic regression | 20 |
commonly used | 20 |
mouth disease | 20 |
mg dl | 20 |
lymph node | 20 |
vaccinia virus | 19 |
randomized controlled | 19 |
family history | 19 |
pulmonary function | 19 |
ethnoveterinary practices | 19 |
respiratory diseases | 19 |
risk prediction | 19 |
abdominal pain | 19 |
cfr ma | 19 |
excess mortality | 19 |
neutrophil count | 19 |
adverse events | 19 |
induction therapy | 19 |
recent studies | 19 |
broad spectrum | 19 |
vascular malformations | 19 |
wave bioreactor | 19 |
per patient | 19 |
closely related | 19 |
rna virus | 19 |
age years | 19 |
real time | 19 |
molecular detection | 19 |
rna synthesis | 19 |
lung slices | 19 |
significantly associated | 19 |
communicable diseases | 19 |
serum samples | 19 |
surveillance systems | 19 |
cell viability | 19 |
zeta potential | 19 |
widely used | 19 |
cultured cells | 19 |
positive results | 19 |
first year | 19 |
hearing loss | 19 |
host disease | 19 |
patient developed | 19 |
tested positive | 19 |
prospective studies | 19 |
analysis method | 19 |
control programmes | 19 |
domestic animals | 19 |
cell entry | 19 |
host cell | 19 |
control strategies | 19 |
kidney injury | 18 |
health outcomes | 18 |
prediction models | 18 |
influenza vaccines | 18 |
inflammatory response | 18 |
included patients | 18 |
malaria infection | 18 |
controlled trial | 18 |
confirmed highly | 18 |
mass gatherings | 18 |
phase i | 18 |
containment areas | 18 |
pediatric patient | 18 |
treated cells | 18 |
explanatory power | 18 |
whole exome | 18 |
fusion proteins | 18 |
lf models | 18 |
analysis revealed | 18 |
infected animals | 18 |
medical record | 18 |
higher risk | 18 |
disease progression | 18 |
ill patients | 18 |
test data | 18 |
von willebrand | 18 |
septic shock | 18 |
neuraminidase activity | 18 |
gold standard | 18 |
complement activation | 18 |
reference genes | 18 |
whole blood | 18 |
viral entry | 18 |
vod sos | 18 |
primary care | 18 |
case report | 18 |
commercial elisa | 18 |
ifn production | 18 |
high mortality | 18 |
acquired respiratory | 18 |
high dose | 18 |
ng ml | 18 |
regression models | 18 |
immunocompromised patients | 18 |
mobile phone | 18 |
life technologies | 18 |
cytokine production | 18 |
rapid detection | 18 |
intcp cells | 18 |
soft tissue | 18 |
surgical resection | 18 |
big data | 18 |
ivig group | 18 |
respiratory infection | 18 |
host immune | 18 |
blood flow | 18 |
antibody responses | 18 |
quality improvement | 18 |
scarlet fever | 17 |
hospitalized children | 17 |
viral loads | 17 |
cancer therapy | 17 |
acute kidney | 17 |
transmission probability | 17 |
bacteremia prediction | 17 |
well tolerated | 17 |
asymptomatic patients | 17 |
virus strain | 17 |
respiratory samples | 17 |
developing countries | 17 |
dengue virus | 17 |
six patients | 17 |
traditional knowledge | 17 |
ewing sarcoma | 17 |
competing interests | 17 |
presenting cells | 17 |
significant reduction | 17 |
west nile | 17 |
hospital medical | 17 |
electronic medical | 17 |
genome sequence | 17 |
patients without | 17 |
brain barrier | 17 |
deficient mice | 17 |
animal health | 17 |
brain tumors | 17 |
data analysis | 17 |
predictive value | 17 |
cancer diagnosis | 17 |
fusion peptide | 17 |
rsv bronchiolitis | 17 |
amino acids | 17 |
pet ct | 17 |
study showed | 17 |
similar results | 17 |
bacterial pathogens | 17 |
wiv formulation | 17 |
viral pathogens | 17 |
animals immunized | 17 |
patients hospitalized | 17 |
invasive fungal | 17 |
salmonella enterica | 17 |
residual disease | 17 |
acute bronchiolitis | 17 |
pneumocystis jirovecii | 17 |
simulation results | 17 |
vaccine efficacy | 17 |
novel coronavirus | 17 |
lung transplantation | 17 |
nucleic acids | 17 |
protein levels | 17 |
intravenous immunoglobulin | 17 |
significant increase | 17 |
data stream | 17 |
human bocavirus | 17 |
aged years | 17 |
free survival | 16 |
index case | 16 |
recent study | 16 |
infection may | 16 |
virus detection | 16 |
pathogenic bacteria | 16 |
phylogenetic analysis | 16 |
side effect | 16 |
severe illness | 16 |
one year | 16 |
syndrome virus | 16 |
first case | 16 |
ex vivo | 16 |
listeria monocytogenes | 16 |
retinoic acid | 16 |
results indicate | 16 |
differential diagnosis | 16 |
three models | 16 |
neutralizing antibody | 16 |
fusion peptides | 16 |
biosecurity measures | 16 |
drug release | 16 |
viral particles | 16 |
patients developed | 16 |
within days | 16 |
reproduction number | 16 |
also used | 16 |
measured using | 16 |
close contact | 16 |
nine patients | 16 |
year post | 16 |
adults aged | 16 |
group i | 16 |
active site | 16 |
prevalence data | 16 |
positive control | 16 |
following sars | 16 |
national institute | 16 |
surface ntcp | 16 |
less likely | 16 |
airway pressure | 16 |
molar mass | 16 |
igy titers | 16 |
health systems | 16 |
medical care | 16 |
like illness | 16 |
bacterial pneumonia | 16 |
protein kinase | 16 |
clinical symptoms | 16 |
tissue culture | 16 |
critical care | 15 |
thermo fisher | 15 |
key role | 15 |
pain crisis | 15 |
commercially available | 15 |
study aimed | 15 |
day post | 15 |
infectious peritonitis | 15 |
antibody response | 15 |
cns tumors | 15 |
hepatocellular carcinoma | 15 |
predicted epitopes | 15 |
late effects | 15 |
deficient covs | 15 |
natural infection | 15 |
leading cause | 15 |
antimicrobial peptides | 15 |
population density | 15 |
nested pcr | 15 |
antiviral drugs | 15 |
positive cells | 15 |
population coverage | 15 |
cell cycle | 15 |
acute lung | 15 |
antibody titers | 15 |
i binding | 15 |
copy number | 15 |
productive infection | 15 |
envelope glycoprotein | 15 |
feline infectious | 15 |
hsct patients | 15 |
laboratory data | 15 |
higher incidence | 15 |
environmental factors | 15 |
environmental health | 15 |
oncology group | 15 |
wild type | 15 |
role models | 15 |
viral isolation | 15 |
southeast asia | 15 |
chronic lung | 15 |
neuropathic pain | 15 |
absolute neutrophil | 15 |
patients presenting | 15 |
bronchoalveolar lavage | 15 |
methionine aminopeptidase | 15 |
measles virus | 15 |
stem cells | 15 |
total number | 15 |
may help | 15 |
significant risk | 15 |
rna replicates | 15 |
produce contamination | 15 |
perivascular spaces | 15 |
complete genome | 15 |
income countries | 15 |
risk neuroblastoma | 15 |
viral genome | 15 |
megaterium mtcc | 15 |
culture rate | 15 |
disease outbreak | 15 |
spike glycoprotein | 15 |
severe hemophilia | 15 |
calculated using | 15 |
carv infection | 15 |
mm hg | 15 |
transmission electron | 15 |
cancer patients | 15 |
among patients | 15 |
per well | 15 |
adaptive immune | 15 |
median follow | 15 |
cancer cells | 15 |
training data | 15 |
scd patients | 15 |
parent virus | 15 |
reported hh | 15 |
lowest rmse | 15 |
heart disease | 15 |
better understand | 15 |
major cause | 14 |
regression model | 14 |
inhibitory effects | 14 |
red cell | 14 |
pathogens may | 14 |
mvamesoa del | 14 |
clinical management | 14 |
induction chemotherapy | 14 |
seven days | 14 |
low levels | 14 |
bile acid | 14 |
hypertonic saline | 14 |
test results | 14 |
mers patients | 14 |
airway epithelial | 14 |
life cycle | 14 |
viral protein | 14 |
one health | 14 |
antiviral response | 14 |
among pediatric | 14 |
screening program | 14 |
lung tissue | 14 |
may occur | 14 |
cell bank | 14 |
complement signaling | 14 |
blood transfusion | 14 |
time point | 14 |
patients may | 14 |
chikungunya virus | 14 |
adherence rates | 14 |
graphpad prism | 14 |
foodborne pathogens | 14 |
sense rna | 14 |
primary human | 14 |
exact test | 14 |
first line | 14 |
pilot study | 14 |
experimental cerebral | 14 |
associated pneumonia | 14 |
literature review | 14 |
may lead | 14 |
allogeneic hematopoietic | 14 |
isothermal amplification | 14 |
potential therapeutic | 14 |
tcd screening | 14 |
jirovecii pneumonia | 14 |
housekeeping genes | 14 |
zikv neonates | 14 |
organ failure | 14 |
multiplex pcr | 14 |
bereaved parents | 14 |
severe respiratory | 14 |
expression system | 14 |
mers coronavirus | 14 |
pedv strains | 14 |
burkitt lymphoma | 14 |
lung slice | 14 |
health threats | 14 |
human neutralizing | 14 |
recombinant factor | 14 |
avian coronavirus | 14 |
longitudinal data | 14 |
early detection | 14 |
binding prediction | 14 |
ingreso en | 14 |
tyrosine kinase | 14 |
endocytosis signal | 14 |
particle size | 14 |
clinical impact | 14 |
will help | 14 |
genetic testing | 14 |
mcar antibodies | 14 |
response rate | 14 |
complete remission | 14 |
risk patients | 14 |
false positive | 14 |
interferon production | 14 |
target cells | 14 |
may play | 14 |
cov clpro | 14 |
viral isolates | 14 |
lpaiv infection | 14 |
complement pathway | 14 |
case fatality | 14 |
patient care | 14 |
liver biopsy | 14 |
pao fio | 14 |
secondary cases | 14 |
descriptive statistics | 14 |
target genes | 13 |
communication skills | 13 |
case reports | 13 |
immune reconstitution | 13 |
mononuclear cells | 13 |
tumor necrosis | 13 |
protein synthesis | 13 |
mavs signaling | 13 |
cada horas | 13 |
nasal swabs | 13 |
icu admission | 13 |
year survival | 13 |
two weeks | 13 |
cd cells | 13 |
learning models | 13 |
relatively low | 13 |
ethics committee | 13 |
cd cd | 13 |
successfully treated | 13 |
global burden | 13 |
high grade | 13 |
farm animals | 13 |
hematologic malignancies | 13 |
disease prediction | 13 |
complete protection | 13 |
recombinant viruses | 13 |
cell types | 13 |
seven patients | 13 |
lymphatic vessels | 13 |
transcription polymerase | 13 |
indirect elisa | 13 |
clinically significant | 13 |
human rhinovirus | 13 |
reported cases | 13 |
cell epitopes | 13 |
mortality associated | 13 |
global health | 13 |
infected astrocytes | 13 |
use research | 13 |
wild bird | 13 |
also reported | 13 |
broadly neutralizing | 13 |
eligible patients | 13 |
patients admitted | 13 |
yellow fever | 13 |
blood counts | 13 |
increased severity | 13 |
con el | 13 |
los pacientes | 13 |
query data | 13 |
fusion promotion | 13 |
days later | 13 |
strand rna | 13 |
viral proteins | 13 |
nh cl | 13 |
among different | 13 |
coronavirus spike | 13 |
search query | 13 |
binding domain | 13 |
also showed | 13 |
chronic transfusion | 13 |
fever virus | 13 |
sample size | 13 |
goat anti | 13 |
specific antibody | 13 |
marrow transplant | 13 |
poor prognosis | 13 |
passive inhalation | 13 |
acute phase | 13 |
antimicrobial resistance | 13 |
aeruginosa mtcc | 13 |
hospital stay | 13 |
pfu ml | 13 |
solid tumor | 13 |
feline coronavirus | 13 |
las infecciones | 13 |
physical examination | 13 |
severe anemia | 13 |
en caso | 13 |
viral fusion | 13 |
term follow | 13 |
fio ratio | 13 |
drug resistance | 13 |
ds aml | 13 |
liquid chromatography | 13 |
supporting information | 13 |
univariate analysis | 13 |
study design | 13 |
evaluated using | 13 |
mice infected | 13 |
mouse models | 13 |
viral bronchiolitis | 13 |
medical examiners | 13 |
related complications | 13 |
fusion protein | 13 |
clinical sample | 13 |
smooth muscle | 13 |
patient received | 13 |
aerosol route | 13 |
secondary bacterial | 13 |
hn mutations | 12 |
pandemic potential | 12 |
within months | 12 |
drug administration | 12 |
three years | 12 |
influenza mortality | 12 |
pedv infection | 12 |
serum igy | 12 |
cd count | 12 |
human airway | 12 |
conjugated secondary | 12 |
subunit vaccine | 12 |
may provide | 12 |
highly conserved | 12 |
healthcare workers | 12 |
cells expressing | 12 |
pmo targeting | 12 |
six months | 12 |
pain control | 12 |
bronchiolitis obliterans | 12 |
confocal laser | 12 |
viral shedding | 12 |
prism software | 12 |
nipah virus | 12 |
community cohort | 12 |
hazard ratio | 12 |
virus strains | 12 |
passive administration | 12 |
gap mcb | 12 |
vsv rna | 12 |
salmonella typhimurium | 12 |
mesothelin expressing | 12 |
human population | 12 |
study group | 12 |
measles transmissions | 12 |
treatment options | 12 |
cattle herds | 12 |
pancreatic cancer | 12 |
within hours | 12 |
dromedary camels | 12 |
binding protein | 12 |
ethyl acetate | 12 |
economic losses | 12 |
graft failure | 12 |
retrospective analysis | 12 |
prediction graphs | 12 |
mediated isothermal | 12 |
en un | 12 |
body cavity | 12 |
cynomolgus macaques | 12 |
practice guidelines | 12 |
i alleles | 12 |
improve patient | 12 |
culture medium | 12 |
studies using | 12 |
situ hybridization | 12 |
conjugated morpholino | 12 |
nile virus | 12 |
arterivirus nsp | 12 |
physical activity | 12 |
maintenance therapy | 12 |
multiplex real | 12 |
bbb permeability | 12 |
diagnostic testing | 12 |
allele frequency | 12 |
macrolide combination | 12 |
detection mix | 12 |
dnn models | 12 |
gel electrophoresis | 12 |
gastroenteritis virus | 12 |
bacterial cells | 12 |
chronic rhinosinusitis | 12 |
health infrastructure | 12 |
buffered saline | 12 |
respiratory pathogens | 12 |
vlp antibodies | 12 |
factors associated | 12 |
cervical cancer | 12 |
platelet aggregation | 12 |
samples collected | 12 |
kvhvq motif | 12 |
less effective | 12 |
nucleocytoplasmic trafficking | 12 |
direct contact | 12 |
korea outbreak | 12 |
bovine serum | 12 |
mda data | 12 |
clinical microbiology | 12 |
dna viruses | 12 |
indigenous communities | 12 |
mda mf | 12 |
porcine reproductive | 12 |
inflammatory cytokine | 12 |
two months | 12 |
total rna | 12 |
neutralizing activities | 12 |
cell count | 12 |
cell receptor | 12 |
riesgo para | 12 |
symptom onset | 12 |
survey data | 12 |
acute viral | 12 |
lf elimination | 12 |
patient outcomes | 12 |
cov patients | 12 |
treated patients | 12 |
population flows | 12 |
immune cell | 12 |
morpholino oligomer | 12 |
clinical evaluation | 12 |
cancer center | 12 |
secondary antibodies | 12 |
like receptors | 12 |
initial antibiotics | 12 |
virus vaccine | 12 |
peak airway | 12 |
based guidelines | 12 |
infected erythrocytes | 12 |
high levels | 12 |
brief exposure | 12 |
globin gene | 12 |
gram negativos | 12 |
febrile neutropenia | 12 |
food safety | 12 |
fatality rate | 12 |
stage iv | 12 |
host defense | 12 |
human respiratory | 11 |
every year | 11 |
potential risk | 11 |
clinical specimens | 11 |
pg ml | 11 |
aged less | 11 |
dry powder | 11 |
also identified | 11 |
lessons learned | 11 |
local geo | 11 |
social network | 11 |
plaque assay | 11 |
kvhvq motifs | 11 |
year period | 11 |
highly effective | 11 |
receiving prone | 11 |
virus via | 11 |
following quotation | 11 |
albumin binding | 11 |
study included | 11 |
jak stat | 11 |
study population | 11 |
prostate cancer | 11 |
treatment related | 11 |
rabbit mab | 11 |
molecular biology | 11 |
bleeding episodes | 11 |
virus entry | 11 |
emcv infection | 11 |
plant species | 11 |
identify patients | 11 |
wbc count | 11 |
year overall | 11 |
site ii | 11 |
molecular weight | 11 |
risk stratification | 11 |
nitric oxide | 11 |
pcr detection | 11 |
partial protection | 11 |
particle vaccine | 11 |
input variables | 11 |
viral pneumonia | 11 |
early stage | 11 |
ifn induction | 11 |
marrow evaluation | 11 |
nosocomial transmission | 11 |
obstruction syndrome | 11 |
clinical significance | 11 |
antigen alone | 11 |
another study | 11 |
joint disease | 11 |
hct recipients | 11 |
causative agent | 11 |
health authorities | 11 |
relatively high | 11 |
prediction performance | 11 |
well plate | 11 |
assessment tool | 11 |
single institution | 11 |
two motifs | 11 |
three independent | 11 |
mhv nsp | 11 |
poultry trade | 11 |
acute lower | 11 |
data obtained | 11 |
physical therapy | 11 |
induced lung | 11 |
proteasome pathway | 11 |
laser scanning | 11 |
mrna levels | 11 |
mers cases | 11 |
months post | 11 |
ecmo therapy | 11 |
determined using | 11 |
considered significant | 11 |
prevention strategies | 11 |
vaccine formulation | 11 |
several studies | 11 |
transgenic mice | 11 |
eight patients | 11 |
next generation | 11 |
iu kg | 11 |
high affinity | 11 |
increased expression | 11 |
unrelated donor | 11 |
lung lobes | 11 |
mediated immune | 11 |
ltx recipients | 11 |
year os | 11 |
south africa | 11 |
saharan africa | 11 |
plasma cells | 11 |
case highlights | 11 |
vero cell | 11 |
critical step | 11 |
gof experiments | 11 |
patients experienced | 11 |
infections caused | 11 |
fisher scientific | 11 |
tgf beta | 11 |
human health | 11 |
vaccine formulations | 11 |
level local | 11 |
chemical conjugation | 11 |
first reported | 11 |
active administration | 11 |
human monoclonal | 11 |
induced apoptosis | 11 |
two years | 11 |
also observed | 11 |
entry process | 11 |
based vaccine | 11 |
plant pathogens | 11 |
epidemiological data | 11 |
laboratory findings | 11 |
th century | 11 |
adult animals | 11 |
virus titer | 11 |
study shows | 11 |
european union | 11 |
conducted using | 11 |
lactam macrolide | 11 |
aml patients | 11 |
medical history | 11 |
previous research | 11 |
cxr findings | 11 |
mass gathering | 11 |
may result | 11 |
versus host | 11 |
control mice | 11 |
influenza epidemics | 11 |
cell activation | 11 |
quality assurance | 11 |
peptide binding | 11 |
factor ix | 11 |
dairy cattle | 11 |
tumor cell | 11 |
average age | 11 |
bleeding disorder | 11 |
autosomal recessive | 11 |
institutional review | 11 |
packed red | 11 |
specific antibodies | 11 |
gene mutation | 11 |
positive pneumonia | 11 |
cells using | 11 |
ngt peg | 11 |
renal disease | 11 |
partial response | 11 |
related mortality | 11 |
ge healthcare | 11 |
may cause | 11 |
results suggested | 11 |
environmental conditions | 11 |
retrospectively reviewed | 11 |
structural proteins | 11 |
negative results | 11 |
stress granule | 11 |
blood count | 11 |
currently available | 11 |
birth weight | 11 |
surveillance study | 11 |
animal care | 11 |
bajaur agency | 11 |
marrow biopsy | 11 |
spectrum antibiotics | 11 |
safety profile | 11 |
clinical outcome | 11 |
mucosal immune | 11 |
type mice | 11 |
oxygen saturation | 11 |
climate change | 11 |
also shown | 11 |
severe pneumonia | 11 |
novel human | 11 |
ii binding | 11 |
sars coronavirus | 11 |
cell lymphoma | 11 |
ic values | 11 |
common cause | 11 |
complete blood | 11 |
different concentrations | 11 |
delta inulin | 11 |
intensive chemotherapy | 11 |
san diego | 11 |
bacillus megaterium | 11 |
hpiv type | 11 |
iv antibiotics | 11 |
two cases | 11 |
isolation strategies | 11 |
different time | 11 |
infected cell | 11 |
stage malaria | 11 |
en pacientes | 10 |
improve outcomes | 10 |
foodborne diseases | 10 |
fold higher | 10 |
may reflect | 10 |
cells per | 10 |
developmental delay | 10 |
protective equipment | 10 |
marrow aspirate | 10 |
cx cl | 10 |
achieve mf | 10 |
rodent models | 10 |
serum ferritin | 10 |
wide variety | 10 |
well studied | 10 |
family members | 10 |
inflammatory cells | 10 |
disease occurrence | 10 |
performance liquid | 10 |
air pollutants | 10 |
independent experiments | 10 |
new zealand | 10 |
patients will | 10 |
coronavirus replication | 10 |
isothermal mastermix | 10 |
biosafety level | 10 |
occlusive crisis | 10 |
foodborne illness | 10 |
intramuscular injection | 10 |
collected data | 10 |
pneumocystis pneumonia | 10 |
human serum | 10 |
important factor | 10 |
patients met | 10 |
vaccine design | 10 |
sodium sulfate | 10 |
molecule inhibitors | 10 |
santa cruz | 10 |
pain scores | 10 |
immunofluorescent assay | 10 |
genome sequencing | 10 |
lung pathology | 10 |
stage iii | 10 |
bovine coronavirus | 10 |
virus particles | 10 |
expression systems | 10 |
negative patients | 10 |
blood tissue | 10 |
following specifications | 10 |
viral dna | 10 |
bal samples | 10 |
hemoglobin electrophoresis | 10 |
coronavirus infections | 10 |
progressive disease | 10 |
per year | 10 |
humoral immunity | 10 |
behavioral adherence | 10 |
pp ab | 10 |
review board | 10 |
side chain | 10 |
negative controls | 10 |
naturally infected | 10 |
virus genome | 10 |
community acquired | 10 |
fomite route | 10 |
graft versus | 10 |
culture supernatants | 10 |
studies suggest | 10 |
mers transmission | 10 |
clinical research | 10 |
inhibitory activity | 10 |
stress granules | 10 |
children undergoing | 10 |
pdsa cycles | 10 |
liquid hu | 10 |
exchange transfusion | 10 |
ifn signaling | 10 |
disease caused | 10 |
diagnostic test | 10 |
cell therapy | 10 |
cotransporting polypeptide | 10 |
global mortality | 10 |
influenza ah | 10 |
ag mice | 10 |
neutralizing monoclonal | 10 |
diabetes mellitus | 10 |
cancer treatment | 10 |
produce safety | 10 |
pregnant women | 10 |
also associated | 10 |
gestational age | 10 |
natural killer | 10 |
prediction uncertainty | 10 |
recombinant pedvs | 10 |
ha dose | 10 |
purified pedv | 10 |
thoracic society | 10 |
pneumonia severity | 10 |
antibacterial activity | 10 |
antiviral drug | 10 |
day survival | 10 |
twitter data | 10 |
best data | 10 |
cell acute | 10 |
subgroup analysis | 10 |
high rate | 10 |
may represent | 10 |
statistical analyses | 10 |
based methods | 10 |
early stages | 10 |
causative agents | 10 |
respiratory rate | 10 |
treatment group | 10 |
clinical diagnosis | 10 |
pandemic virus | 10 |
con un | 10 |
described earlier | 10 |
controlled trials | 10 |
related ards | 10 |
molecular docking | 10 |
nonstructural protein | 10 |
systematic analysis | 10 |
animal model | 10 |
capita gdp | 10 |
tcd velocities | 10 |
supplementary material | 10 |
inhibitory effect | 10 |
early diagnosis | 10 |
university hospital | 10 |
health workers | 10 |
experimental infection | 10 |
initial presentation | 10 |
nasal discharge | 10 |
extracellular matrix | 10 |
pediatric aml | 10 |
bioreactor system | 10 |
also tested | 10 |
month period | 10 |
pcr assays | 10 |
pulmonary disease | 10 |
job experience | 10 |
relacionada con | 10 |
fetal bovine | 10 |
post hoc | 10 |
hn protein | 10 |
poultry imports | 10 |
supplementary data | 10 |
infected red | 10 |
wide range | 10 |
microbiological safety | 10 |
hydroxyurea use | 10 |
herpes virus | 10 |
bl mice | 10 |
tract disease | 10 |
necrosis factor | 10 |
mediated endocytosis | 10 |
treatment option | 10 |
cov spike | 10 |
serum albumin | 10 |
adverse effects | 10 |
biological weapons | 10 |
two different | 10 |
rapid diagnostic | 10 |
neutralization titers | 10 |
global public | 10 |
significant impact | 10 |
taurocholate cotransporting | 10 |
splenic sequestration | 10 |
mapk pathway | 10 |
severe cap | 10 |
nasal cavity | 10 |
significant decrease | 10 |
western blotting | 10 |
north america | 10 |
i molecules | 10 |
data demonstrate | 10 |
first time | 10 |
encephalomyocarditis virus | 10 |
pneumonia patients | 10 |
viral sampling | 10 |
ntcp expression | 10 |
search data | 10 |
stage parasites | 10 |
vivo experiments | 10 |
molecular techniques | 10 |
scientific community | 10 |
ctl epitopes | 10 |
clinical strains | 10 |
functional receptor | 10 |
transcription factor | 10 |
pulmonary exacerbations | 10 |
within weeks | 10 |
viral detection | 10 |
dipeptidyl peptidase | 10 |
one hundred | 10 |
state university | 10 |
enteric bacteria | 10 |
extremely low | 10 |
irb approval | 10 |
human influenza | 10 |
bhk cells | 9 |
tissue pathology | 9 |
different age | 9 |
induced anti | 9 |
weight gain | 9 |
sample collection | 9 |
binding lectin | 9 |
training programs | 9 |
plate reader | 9 |
renal function | 9 |
respiratory support | 9 |
available data | 9 |
preliminary data | 9 |
cavity effusions | 9 |
control strategy | 9 |
trend towards | 9 |
hydroxyurea treatment | 9 |
containment scale | 9 |
patients showed | 9 |
inducible gene | 9 |
pure product | 9 |
medicinal plant | 9 |
cell wall | 9 |
lateral flow | 9 |
aspergillus fumigatus | 9 |
persistent infection | 9 |
control inputs | 9 |
tidal volume | 9 |
average number | 9 |
may benefit | 9 |
antigen detection | 9 |
synovial sarcoma | 9 |
mm nacl | 9 |
female presented | 9 |
treated group | 9 |
deep sequencing | 9 |
cell populations | 9 |
factors affecting | 9 |
patients reported | 9 |
least three | 9 |
chronic gvhd | 9 |
promising candidate | 9 |
social containment | 9 |
last years | 9 |
plasma membrane | 9 |
virus challenge | 9 |
wound healing | 9 |
cl care | 9 |
crucial role | 9 |
antibiotic therapy | 9 |
higher among | 9 |
targeted therapies | 9 |
organ transplantation | 9 |
also important | 9 |
scanning microscopy | 9 |
diarrhoea virus | 9 |
human transmission | 9 |
minimal residual | 9 |
ed length | 9 |
aerosol infection | 9 |
murine coronavirus | 9 |
vaccine candidate | 9 |
candida species | 9 |
cc kg | 9 |
platelet function | 9 |
mediated immunity | 9 |
junto con | 9 |
reactive protein | 9 |
health emergencies | 9 |
airway epithelium | 9 |
challenge virus | 9 |
field strains | 9 |
total score | 9 |
done using | 9 |
detected using | 9 |
serially diluted | 9 |
bloodstream infections | 9 |
solid organ | 9 |
per group | 9 |
past year | 9 |
dose steroids | 9 |
patients achieved | 9 |
cause mortality | 9 |
informed models | 9 |
weather data | 9 |
deletion duplication | 9 |
japanese encephalitis | 9 |
congenital heart | 9 |
phosphorodiamidate morpholino | 9 |
months later | 9 |
associated infections | 9 |
fellowship programs | 9 |
severity index | 9 |
genetically modified | 9 |
time period | 9 |
major role | 9 |
es el | 9 |
highest explanatory | 9 |
baseline characteristics | 9 |
comparative analysis | 9 |
smallpox vaccine | 9 |
nucleocapsid protein | 9 |
antibiotic resistance | 9 |
immunosorbent assay | 9 |
metastatic potential | 9 |
antibiotics regimen | 9 |
sodium taurocholate | 9 |
abortive infection | 9 |
therapeutic options | 9 |
organ dysfunction | 9 |
liver enzymes | 9 |
mm tris | 9 |
water sources | 9 |
ring vaccination | 9 |
rabbit anti | 9 |
relative importance | 9 |
function tests | 9 |
patient presented | 9 |
old caucasian | 9 |
binding affinity | 9 |
mva virus | 9 |
broad range | 9 |
patients enrolled | 9 |
medical conditions | 9 |
cell lysates | 9 |
occlusive disease | 9 |
healthy donors | 9 |
quantitative pcr | 9 |
limited data | 9 |
viral attachment | 9 |
responded well | 9 |
un aumento | 9 |
local health | 9 |
leukemia cells | 9 |
using graphpad | 9 |
data points | 9 |
human infection | 9 |
rna replication | 9 |
data available | 9 |
secondary infections | 9 |
study also | 9 |
predictive performance | 9 |
protective effect | 9 |
care workers | 9 |
among hcws | 9 |
patients presented | 9 |
primary astrocytes | 9 |
may increase | 9 |
cov outbreak | 9 |
pediatric intensive | 9 |
ml min | 9 |
clinical decision | 9 |
atypical hus | 9 |
randomized clinical | 9 |
poc testing | 9 |
signaling pathways | 9 |
drug delivery | 9 |
many patients | 9 |
guinea pigs | 9 |
sequence analysis | 9 |
infectious agent | 9 |
cell adhesion | 9 |
por el | 9 |
based social | 9 |
mice lacking | 9 |
study sites | 9 |
processing pathways | 9 |
breakthrough cinv | 9 |
receiving chemotherapy | 9 |
survival rate | 9 |
cell anemia | 9 |
west africa | 9 |
extremely rare | 9 |
house indirect | 9 |
large numbers | 9 |
optimal cut | 9 |
kidney disease | 9 |
hydroxyurea therapy | 9 |
personal protective | 9 |
months old | 9 |
viral etiology | 9 |
developing fetuses | 9 |
clinical isolate | 9 |
also play | 9 |
autoimmune hemolytic | 9 |
uninfected cells | 9 |
avian species | 9 |
antibiotic use | 9 |
clinical manifestations | 9 |
blot analysis | 9 |
cohort studies | 9 |
policy makers | 9 |
malaria parasite | 9 |
patient samples | 9 |
newly identified | 9 |
time polymerase | 9 |
based approach | 9 |
study conducted | 9 |
aml cells | 9 |
based vaccination | 9 |
increased mortality | 9 |
lower risk | 9 |
sectional study | 9 |
baculovirus expression | 9 |
transmission routes | 9 |
antigen presenting | 9 |
bacterial membrane | 9 |
chronic diseases | 9 |
significantly improved | 9 |
antiviral therapy | 9 |
likely due | 9 |
bal fluid | 9 |
genes involved | 9 |
testing revealed | 9 |
highly sensitive | 9 |
single agent | 9 |
guinea pig | 9 |
ii molecules | 9 |
acute leukemia | 9 |
treatment failure | 9 |
control patients | 9 |
treatment modalities | 9 |
human interaction | 9 |
lysis buffer | 9 |
leader protein | 9 |
magnetic resonance | 9 |
advax blp | 9 |
lethal dose | 9 |
ibv strains | 9 |
cd car | 9 |
high index | 9 |
molecular characterization | 9 |
knockout mice | 9 |
internet search | 9 |
daily basis | 9 |
studies demonstrated | 9 |
rabv infection | 9 |
antiviral effects | 9 |
terminal region | 9 |
cerebrospinal fluid | 9 |
previous reports | 9 |
information gained | 9 |
hpiv types | 9 |
autoimmune disease | 9 |
mortality among | 9 |
serum creatinine | 9 |
mda coverage | 9 |
will allow | 9 |
bleeding symptoms | 9 |
connective tissue | 9 |
una enfermedad | 9 |
alveolar macrophages | 9 |
degenerative joint | 9 |
mammalian cells | 9 |
acid sequence | 9 |
one hand | 9 |
mice treated | 9 |
pediatric cancers | 9 |
better understanding | 9 |
tlr agonist | 9 |
contact tracing | 9 |
study found | 9 |
igg antibodies | 9 |
negative predictive | 9 |
muscular dystrophy | 9 |
nk cell | 9 |
highly contagious | 9 |
recombinant baculovirus | 9 |
nonhuman primates | 9 |
disease burden | 9 |
metastatic wt | 9 |
bad news | 9 |
thalassemia trait | 9 |
pediatric ward | 9 |
effective vaccination | 9 |
compartment population | 9 |
ring stage | 9 |
plants used | 9 |
per cent | 9 |
epidemic diarrhoea | 9 |
interferon signaling | 9 |
antisense morpholino | 9 |
also revealed | 8 |
organic layer | 8 |
mrna expression | 8 |
type ii | 8 |
may reduce | 8 |
malaria parasites | 8 |
multiple viral | 8 |
falciparum malaria | 8 |
pedv variants | 8 |
conjugated pmo | 8 |
developed countries | 8 |
developing world | 8 |
family medicine | 8 |
quantified using | 8 |
pedv binding | 8 |
median dose | 8 |
two decades | 8 |
data indicate | 8 |
clinical response | 8 |
infectious complications | 8 |
research hospital | 8 |
start site | 8 |
viral disease | 8 |
pattern recognition | 8 |
infectious virus | 8 |
days vs | 8 |
control study | 8 |
patients died | 8 |
intraperitoneally injected | 8 |
associated protein | 8 |
high viral | 8 |
newly developed | 8 |
rna expression | 8 |
marburg virus | 8 |
years later | 8 |
inhibit viral | 8 |
copies per | 8 |
sfd powder | 8 |
potent neutralizing | 8 |
rare case | 8 |
transmission dynamics | 8 |
peritoneal macrophages | 8 |
analysis methods | 8 |
con una | 8 |
cytopathic effects | 8 |
low bmd | 8 |
care providers | 8 |
blp adjuvanted | 8 |
novel antiviral | 8 |
significantly less | 8 |
point agarose | 8 |
infection via | 8 |
measles vaccine | 8 |
extraneural metastases | 8 |
biological activity | 8 |
mediated degradation | 8 |
infection risk | 8 |
factors influencing | 8 |
southern region | 8 |
sars cov | 8 |
targeted therapy | 8 |
clinically confirmed | 8 |
care units | 8 |
oncology fellowship | 8 |
sick patient | 8 |
national institutes | 8 |
ethnoveterinary knowledge | 8 |
saudi moh | 8 |
reporting system | 8 |
risk groups | 8 |
long time | 8 |
undergoing hsct | 8 |
sudlow i | 8 |
proteolytic cleavage | 8 |
see table | 8 |
i ii | 8 |
bl cells | 8 |
thermo scientific | 8 |
hbv entry | 8 |
emerging viral | 8 |
tertiary care | 8 |
central role | 8 |
dorsal horn | 8 |
agarose gel | 8 |
germ cell | 8 |
body mass | 8 |
low doses | 8 |
secondary antibody | 8 |
gata mutation | 8 |
membrane oxygenation | 8 |
much higher | 8 |
children hospitalized | 8 |
encephalitis virus | 8 |
severe malaria | 8 |
research networks | 8 |
bleeding disorders | 8 |
rural areas | 8 |
health literacy | 8 |
hn dimer | 8 |
bacterial cell | 8 |
regions level | 8 |
cl protease | 8 |
braf fusion | 8 |
silver nitrate | 8 |
professional development | 8 |
million people | 8 |
secondary structures | 8 |
block group | 8 |
pulmonary exacerbation | 8 |
willebrand disease | 8 |
ms ms | 8 |
oral ribavirin | 8 |
murine model | 8 |
international health | 8 |
previously healthy | 8 |
hat inhibitor | 8 |
relative information | 8 |
western blots | 8 |
local control | 8 |
adhesion molecule | 8 |
innate antiviral | 8 |
progeny virus | 8 |
term effects | 8 |
common respiratory | 8 |
count kg | 8 |
systemic symptoms | 8 |
emerging virus | 8 |
multivariate analysis | 8 |
healthcare providers | 8 |
formulation science | 8 |
remains unclear | 8 |
suspected highly | 8 |
standard curve | 8 |
electron microscope | 8 |
vast majority | 8 |
pcr testing | 8 |
integrated approach | 8 |
time rt | 8 |
emerging viruses | 8 |
compared using | 8 |
stat pathway | 8 |
essential role | 8 |
new technologies | 8 |
patients requiring | 8 |
met inclusion | 8 |
lactate dehydrogenase | 8 |
unique case | 8 |
anhydrous sodium | 8 |
voc days | 8 |
group ii | 8 |
studies revealed | 8 |
jc virus | 8 |
soil type | 8 |
past years | 8 |
order nidovirales | 8 |
high quality | 8 |
advanced cancer | 8 |
data set | 8 |
laboratory results | 8 |
duplication analysis | 8 |
renal failure | 8 |
longitudinal study | 8 |
peripheral smear | 8 |
small molecules | 8 |
conditioning regimen | 8 |
hiv envelope | 8 |
cytotoxicity assay | 8 |
different sites | 8 |
blood smear | 8 |
output variable | 8 |
vascular anomalies | 8 |
vsv infection | 8 |
top dnn | 8 |
surface antigen | 8 |
contact route | 8 |
rapid test | 8 |
inactivated virus | 8 |
confirmed pneumonia | 8 |
bacteremia score | 8 |
significant changes | 8 |
primary antibodies | 8 |
neutropenic patients | 8 |
human disease | 8 |
exosomal mir | 8 |
analysis using | 8 |
neutrophil engraftment | 8 |
median days | 8 |
atypical pathogens | 8 |
surface area | 8 |
cov pathogenesis | 8 |
system preparedness | 8 |
cancer institute | 8 |
aldehyde bisulfite | 8 |
seasonal arima | 8 |
greater risk | 8 |
neuroblastoma patients | 8 |
melting point | 8 |
least months | 8 |
therapeutic targets | 8 |
platelet transfusions | 8 |
weighted variance | 8 |
infectious dose | 8 |
examined using | 8 |
dg pl | 8 |
risk group | 8 |
patients infected | 8 |
seres humanos | 8 |
histone deacetylase | 8 |
en una | 8 |
pdsa cycle | 8 |
lymphoblastic lymphoma | 8 |
dual use | 8 |
therapeutic target | 8 |
culture episodes | 8 |
human mabs | 8 |
naver search | 8 |
model model | 8 |
health status | 8 |
extracellular adp | 8 |
ethnoveterinary medicines | 8 |
mirage syndrome | 8 |
executive functioning | 8 |
nasal epithelial | 8 |
outcomes associated | 8 |
moderate cap | 8 |
inflammatory cell | 8 |
ddavp administration | 8 |
showed significant | 8 |
learning model | 8 |
cellular immunity | 8 |
mri showed | 8 |
kinase inhibitor | 8 |
serial interval | 8 |
cox regression | 8 |
cribriform plate | 8 |
pulmonary aspergillosis | 8 |
higher levels | 8 |
blood mononuclear | 8 |
host antiviral | 8 |
male presented | 8 |
air pollution | 8 |
every months | 8 |
published data | 8 |
live mers | 8 |
cell growth | 8 |
local people | 8 |
rational design | 8 |
also inhibited | 8 |
cd ra | 8 |
horas intravenoso | 8 |
tissue samples | 8 |
foodborne disease | 8 |
mice deficient | 8 |
suspected mers | 8 |
nasopharyngeal aspirates | 8 |
contagious diseases | 8 |
resistant bacteria | 8 |
blood pressure | 8 |
culture results | 8 |
para el | 8 |
tissue section | 8 |
successful treatment | 8 |
squared values | 8 |
severe thrombocytopenia | 8 |
well known | 8 |
vesicular stomatitis | 8 |
parameter space | 8 |
southern brazil | 8 |
medical research | 8 |
limited number | 8 |
quality control | 8 |
beta thalassemia | 8 |
hepatic hemangiomas | 8 |
care tests | 8 |
different types | 8 |
signal pathway | 8 |
influenza infections | 8 |
diagnostic tool | 8 |
lesser extent | 8 |
enterica serovar | 8 |
urgent need | 8 |
ntcp protein | 8 |
mucous membranes | 8 |
use committee | 8 |
fold increase | 8 |
positive rpp | 8 |
leptomeningeal enhancement | 8 |
infected individuals | 8 |
positive predictive | 8 |
reticulocyte count | 8 |
mass vaccination | 8 |
contaminated manure | 8 |
disease prevention | 8 |
health facilities | 8 |
rpe cells | 8 |
brain tumor | 8 |
laboratory testing | 8 |
improved performance | 8 |
quantitative real | 8 |
molecular mechanisms | 8 |
mesothelin protein | 8 |
stable disease | 8 |
morphological changes | 8 |
linked immunosorbent | 8 |
receptor signaling | 8 |
virus isolation | 8 |
red cells | 8 |
klebsiella pneumoniae | 8 |
cruz biotechnology | 8 |
enrolled patients | 8 |
pediatric acute | 8 |
based surveillance | 8 |
cytokine release | 8 |
consensus sequence | 8 |
many cases | 8 |
genetic analysis | 8 |
major histocompatibility | 8 |
media big | 8 |
school reentry | 8 |
evidence suggests | 8 |
lymphoid cells | 8 |
data showed | 8 |
rapid identification | 8 |
suspected cases | 8 |
general population | 8 |
receptor cleavage | 8 |
pathogenic contamination | 8 |
infectious compartment | 8 |
per day | 8 |
respir viruses | 8 |
oxidative stress | 8 |
allograft dysfunction | 8 |
ten patients | 8 |
fixed effects | 8 |
unclear whether | 8 |
systemic inflammation | 8 |
ltx patients | 8 |
influenza viral | 8 |
first level | 8 |
future research | 8 |
best practices | 8 |
per week | 8 |
search queries | 8 |
healthcare settings | 8 |
antiviral compounds | 8 |
immune suppression | 8 |
rapid diagnosis | 8 |
patients underwent | 8 |
diagnostic performance | 8 |
several years | 8 |
stimulated genes | 8 |
higher rates | 8 |
pfu mouse | 8 |
digestive problems | 8 |
por lo | 8 |
parainfluenza viruses | 8 |
palliative care | 8 |
last decade | 8 |
mental health | 8 |
stomatitis virus | 8 |
twentieth century | 8 |
myelodysplastic syndrome | 8 |
conventional chemotherapy | 8 |
lung function | 8 |
cultures drawn | 8 |
influenza activity | 8 |
early phase | 8 |
five years | 8 |
cm sec | 8 |
patients using | 8 |
mass spectrometer | 8 |
relative humidity | 8 |
panc tumor | 8 |
bacterial superinfection | 8 |
norwalk virus | 8 |
current knowledge | 8 |
probably due | 8 |
year efs | 8 |
interquartile range | 8 |
month old | 8 |
first infection | 8 |
previous work | 8 |
falciparum parasites | 8 |
working memory | 8 |
studies may | 8 |
decreased histone | 8 |
least two | 8 |
olfactory nerves | 8 |
responses induced | 8 |
natural suckling | 8 |
old mice | 8 |
prone position | 8 |
observational study | 8 |
rhdv vlp | 8 |
lymphoid tissue | 7 |
respiratory coronavirus | 7 |
also included | 7 |
emergency management | 7 |
recombinant protein | 7 |
case study | 7 |
reactive oxygen | 7 |
standard procedures | 7 |
underwent hsct | 7 |
viral membrane | 7 |
provide valuable | 7 |
mtb rif | 7 |
specific clinical | 7 |
first patient | 7 |
alexa fluor | 7 |
rate among | 7 |
effects model | 7 |
laboratory values | 7 |
unique opportunity | 7 |
potential treatment | 7 |
current literature | 7 |
ejection fraction | 7 |
korean society | 7 |
studies showed | 7 |
systemic disease | 7 |
control trial | 7 |
heart failure | 7 |
monkey kidney | 7 |
se asocia | 7 |
among individuals | 7 |
ci wt | 7 |
clinical care | 7 |
opportunistic infections | 7 |
collected included | 7 |
flows among | 7 |
alpha beta | 7 |
detection methods | 7 |
blood capillaries | 7 |
medulloblastoma cell | 7 |
mouse anti | 7 |
hd deferoxamine | 7 |
old girl | 7 |
major differences | 7 |
recognition receptors | 7 |
matched unrelated | 7 |
hh education | 7 |
using different | 7 |
global outbreak | 7 |
assay kit | 7 |
cap patients | 7 |
structural analysis | 7 |
parameter estimation | 7 |
el virus | 7 |
hepatitis virus | 7 |
los seres | 7 |
electronic monitoring | 7 |
obliterans syndrome | 7 |
oxygen species | 7 |
specific monoclonal | 7 |
will provide | 7 |
infection surveillance | 7 |
antibody production | 7 |
time difference | 7 |
small intestine | 7 |
significantly enhanced | 7 |
antigen processing | 7 |
national security | 7 |
cells may | 7 |
mrd negative | 7 |
cytokine levels | 7 |
staff members | 7 |
vsv replication | 7 |
extracorporeal membrane | 7 |
adult ward | 7 |
clinical information | 7 |
gastrointestinal symptoms | 7 |
low ph | 7 |
made using | 7 |
adverse event | 7 |
transfusional iron | 7 |
take advantage | 7 |
parameter correlations | 7 |
accurate diagnosis | 7 |
cytoplasmic tail | 7 |
laboratory animals | 7 |
novel therapeutic | 7 |
human remains | 7 |
molecular diagnostic | 7 |
thalassemia major | 7 |
prbc transfusions | 7 |
provide evidence | 7 |
nutritional status | 7 |
based network | 7 |
pcr analysis | 7 |
arabian peninsula | 7 |
tissue sections | 7 |
duchenne muscular | 7 |
rna copies | 7 |
cardiovascular disease | 7 |
clinical status | 7 |
validation data | 7 |
per person | 7 |
airborne route | 7 |
dynamic compliance | 7 |
series data | 7 |
structural studies | 7 |
infected ltx | 7 |
fluorescent reporter | 7 |
tested mabs | 7 |
blood stage | 7 |
fully understand | 7 |
poorly understood | 7 |
data support | 7 |
avian infectious | 7 |
isotype control | 7 |
may affect | 7 |
practice guideline | 7 |
bleeding phenotype | 7 |
biological attack | 7 |
refractory agvhd | 7 |
horseradish peroxidase | 7 |
mean value | 7 |
nasal swab | 7 |
working group | 7 |
single dose | 7 |
cyclic neutropenia | 7 |
data related | 7 |
human malaria | 7 |
dendritic cell | 7 |
laboratory mice | 7 |
melanoma differentiation | 7 |
control theory | 7 |
clinical development | 7 |
accurate identification | 7 |
autologous stem | 7 |
model uncertainty | 7 |
without significant | 7 |
viral genomes | 7 |
los factores | 7 |
observed among | 7 |
baylor college | 7 |
within one | 7 |
growth factor | 7 |
mallard netherlands | 7 |
persons born | 7 |
medulloblastoma cells | 7 |
blood transfusions | 7 |
four recombinant | 7 |
molecular basis | 7 |
also possible | 7 |
human cytomegalovirus | 7 |
central venous | 7 |
molecular assays | 7 |
mortality risk | 7 |
cxcr cxcr | 7 |
various types | 7 |
left ventricular | 7 |
membrane proteins | 7 |
penicillin streptomycin | 7 |
size distribution | 7 |
software version | 7 |
diagnostic methods | 7 |
genetic diversity | 7 |
influenza risk | 7 |
quarantined cases | 7 |
predict infectious | 7 |
ross river | 7 |
tumor suppressor | 7 |
present lf | 7 |
cervical lymph | 7 |
among young | 7 |
wild animals | 7 |
near future | 7 |
hpv vaccine | 7 |
remaining patients | 7 |
myocardial fibrosis | 7 |
del paciente | 7 |
zikv rna | 7 |
overall mortality | 7 |
clinical studies | 7 |
given year | 7 |
cell suspension | 7 |
gram positivos | 7 |
hospitalized adults | 7 |
health events | 7 |
lv dysfunction | 7 |
hemophagocytic lymphohistiocytosis | 7 |
unusual events | 7 |
previously published | 7 |
may serve | 7 |
state health | 7 |
surveillance activities | 7 |
low concentrations | 7 |
well described | 7 |
developed acute | 7 |
mhc molecules | 7 |
virus bronchiolitis | 7 |
asylum seekers | 7 |
diffuse myocardial | 7 |
wilcoxon rank | 7 |
series analysis | 7 |
protective immunity | 7 |
using descriptive | 7 |
previously shown | 7 |
sexually transmitted | 7 |
viral gene | 7 |
acute infection | 7 |
many studies | 7 |
animals infected | 7 |
clinical benefits | 7 |
viral titer | 7 |
life threatening | 7 |
influenza vaccination | 7 |
lower levels | 7 |
deficient cov | 7 |
epic tm | 7 |
old boy | 7 |
heavy menstrual | 7 |
virus infected | 7 |
es un | 7 |
enriched immunoglobulins | 7 |
steady state | 7 |
required hospitalization | 7 |
dot represents | 7 |
south america | 7 |
invasive pulmonary | 7 |
high performance | 7 |
orally given | 7 |
risk infants | 7 |
antimicrobial activity | 7 |
drug discovery | 7 |
method groups | 7 |
antiviral innate | 7 |
fungal disease | 7 |
increased levels | 7 |
functional hemoglobin | 7 |
mass index | 7 |
international spread | 7 |
common marmoset | 7 |
fellowship program | 7 |
molecular modeling | 7 |
rabv produces | 7 |
among hospitalized | 7 |
virological surveillance | 7 |
results demonstrated | 7 |
amended soils | 7 |
cell products | 7 |
antigen conjugates | 7 |
bloodstream infection | 7 |
cumulative incidence | 7 |
nasopharyngeal swabs | 7 |
biopsy showed | 7 |
significantly elevated | 7 |
thalassemia patients | 7 |
early identification | 7 |
astrocyte end | 7 |
associated cancers | 7 |
hai titers | 7 |
bacteriemias por | 7 |
powder influenza | 7 |
treatment protocols | 7 |
statistically different | 7 |
los microbios | 7 |
pandemic mortality | 7 |
protease inhibitor | 7 |
containment area | 7 |
square test | 7 |
human infections | 7 |
los casos | 7 |
information regarding | 7 |
cognitive impairment | 7 |
african countries | 7 |
infection caused | 7 |
mpo content | 7 |
primary aim | 7 |
liquid nitrogen | 7 |
avian coronaviruses | 7 |
socioeconomic status | 7 |
hepatic sos | 7 |
sialic acid | 7 |
acute gvhd | 7 |
screening tool | 7 |
generalized linear | 7 |
protective efficacy | 7 |
published literature | 7 |
children diagnosed | 7 |
allogeneic hct | 7 |
analyzed retrospectively | 7 |
lytic peptides | 7 |
predicted epitope | 7 |
clinical use | 7 |
significant improvement | 7 |
severe lower | 7 |
sendai virus | 7 |
three different | 7 |
gene i | 7 |
protein vp | 7 |
chemotherapy regimens | 7 |
induces apoptosis | 7 |
willebrand factor | 7 |
conformational changes | 7 |
health risks | 7 |
retrieval signal | 7 |
assess whether | 7 |
limited settings | 7 |
one day | 7 |
large animals | 7 |
virus circulation | 7 |
empiric therapy | 7 |
master mix | 7 |
healthcare system | 7 |
laboratory confirmation | 7 |
physiological saline | 7 |
type mva | 7 |
estimated day | 7 |
swine transmissible | 7 |
health department | 7 |
control samples | 7 |
class iii | 7 |
point mutations | 7 |
clinically relevant | 7 |
microbial contamination | 7 |
sinusoidal obstruction | 7 |
united kingdom | 7 |
culture conditions | 7 |
qualitative study | 7 |
complement deposition | 7 |
content analysis | 7 |
early recognition | 7 |
versus placebo | 7 |
pcr kit | 7 |
antibiotics administration | 7 |
chemotherapeutic agents | 7 |
pulmonary opacity | 7 |
months following | 7 |
significantly inhibited | 7 |